Dr. John C. Araujo MD Medical Oncologist

Dr. John Araujo is a medical oncologist in Houston, Texas and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice for 10 years. Dr. Araujo accepts several types of health insurance, listed below. He is one of 129 doctors at University of Texas M.D. Anderson Cancer Center who specialize in Medical Oncology.

Are you Dr. John Araujo? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology, Genitourinary

Hospital Affiliation

University of Texas M.D. Anderson Cancer Center
Ranked #1 in Cancer

Education & Medical Training

Dartmouth-Hitchcock Medical Center
Residency, Internal Medicine, 2000 - 2003

University of Texas at Houston
Fellowship, Medical Oncology, 2003 - 2006

Loyola University Chicago Stritch School of Medicine
Class of 2000

Certifications & Licensure

American Board of Internal Medicine
Certified 11 years in Internal Medicine

American Board of Internal Medicine
Certified 8 years in Medical Oncology

TX State Medical License
Active through 2013

Publications & Presentations

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Araujo, J. C.,Trudel, G. C.,Saad, F.,Armstrong, A. J.,Yu, E. Y.,Bellmunt, J.,Wilding, G.,McCaffrey, J.,Serrano, S. V.,Matveev, V. B.,Efstathiou, E.,Oudard, S.,Morris, M. J.,Sizer, B.,Goebell, P. J.,Heidenreich, A.,de Bono, J. S.,Begbie, S.,Hong, J. H.,Richardet, E.,Gallardo, E.,Paliwal, P.,Durham, S.,Cheng, S.,Logothetis, C. J.

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
Aparicio, A. M.,Harzstark, A.,Corn, P. G.,Wen, S.,Araujo, J.,Tu, S. M.,Pagliaro, L.,Kim, J.,Millikan, R. E.,Ryan, C. J.,Tannir, N. M.,Zurita, A.,Mathew, P.,Arap, W.,Troncoso, P.,Thall, P.,Logothetis, C. J.

Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Dayyani, F.,Varkaris, A.,Araujo, J. C.,Song, J. H.,Chatterji, T.,Trudel, G. C.,Logothetis, C. J.,Gallick, G. E.

See all 18 publications

Insurances Accepted

  • Aetna Choice POS II
  • BCBS Blue Card PPO
  • BCBS Texas BlueChoice
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by

Specialty

Location

Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.